National Practice Guideline · Spine
Shounuck Patel, DO, Co-Author of the 2025 ASIPP Comprehensive Evidence-Based Guidelines for Regenerative Therapies in Chronic Low Back Pain
The guideline: Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society of Interventional Pain Physicians (ASIPP). Pain Physician. 2025.
Regenerative medicine is increasingly used for chronic low back pain, but not every treatment has the same level of evidence and not every patient is an appropriate candidate.
In 2025, the American Society of Interventional Pain Physicians (ASIPP) published its Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain in Pain Physician. Dr. Shounuck Patel, of The Patel Center for Functional Regeneration in Newport Beach, California, was one of 35 authors who evaluated the evidence for platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and other regenerative approaches to chronic spine pain.
Thirty-three experts participated in formal consensus voting, producing 19 recommendations with 100% agreement. The result is one of the most comprehensive efforts to date to define where regenerative spine treatments may fit into modern low back pain care, and where the evidence is still limited. [1]
Chronic low back pain is not a single disease.
Pain may come from:
Because of this, the ASIPP guidelines emphasize matching a regenerative treatment to a specific clinical diagnosis and anatomical target, rather than treating nonspecific back pain with the same injection for every patient. [1]
For selected patients with discogenic low back pain, intradiscal PRP received:
This means the evidence is supportive but not definitive.
Intradiscal bone marrow aspirate concentrate, or BMAC, received the same rating:
For epidural PRP, including treatment for low back and lower-extremity pain associated with degenerative disc pathology, the evidence was also rated:
The evidence is less mature for other spinal targets.
Facet joint PRP and mesenchymal cell-based injections received Level IV, or limited, evidence.
PRP for the sacroiliac joint also received Level IV/limited evidence. [1]
The emerging concept of treating multiple structures together as a functional spine unit received a low recommendation because high-quality comparative studies remain scarce. [1]
The important takeaway is that regenerative spine treatment is not one single therapy.
Different procedures have different levels of evidence, and the quality of evidence depends on the diagnosis and anatomical target.
Comprehensive
Appropriate regenerative spine treatment begins with diagnosis, not the injection.
The guidelines state that regenerative therapies should be considered only after a thorough diagnostic evaluation establishes clinical necessity. [1]
Candidates generally have:
Conservative care may include:
Regenerative treatment can complement these approaches rather than replace them.
The central question should not simply be:
“Can PRP help back pain?”
It should be:
“What structure is causing the pain, and does the evidence support treating that structure with PRP, BMAC, or another regenerative approach?”
A major theme of the ASIPP guidelines is that the word “PRP” does not adequately describe a treatment.
PRP products can differ in:
The guideline recommends quality-control measures that include documenting, when clinically feasible:
This matters because two procedures may both be labeled “PRP” while delivering very different biologic products.
BMAC also varies depending on:
Because regenerative products are not uniform pharmaceuticals, how a treatment is harvested, characterized, processed, and delivered can influence its biological characteristics.
ASIPP therefore emphasizes standardization and transparency rather than assuming that every PRP or BMAC procedure is interchangeable. [1]
Comprehensive
One of the strengths of the ASIPP guidelines is that the authors clearly acknowledge what remains uncertain.
High-quality clinical trials are still relatively scarce, and many available studies are small or heterogeneous. [1]
Important unanswered questions include:
PRP studies also vary substantially in how the product is processed and reported, making comparisons between trials difficult. [1]
Evidence for treating the spine as a functional spinal unit remains limited, and the ASIPP guidelines appropriately give this approach a low recommendation because high-quality comparative studies are lacking. [1]
That said, there is a reasonable biological rationale for thinking about the spine as more than a collection of isolated structures.
A spinal motion segment includes multiple interconnected tissues, including:
These tissues function together mechanically. Degeneration or dysfunction in one part of the motion segment can influence loading, motion, and stress in the others.
For example, disc degeneration may alter segmental mechanics and increase stress on the facet joints and supporting soft tissues. Likewise, dysfunction of the posterior elements may change how forces are distributed through the disc and surrounding structures.
This interconnected anatomy helps explain why some patients do not fit neatly into a single pain-generator model. Chronic spine conditions may involve several structures within the same functional unit rather than one isolated source of pain.
That creates a biologic rationale for evaluating the entire painful motion segment and, in selected cases, considering treatment of more than one involved structure.
The practical takeaway is that the functional spinal unit model may help clinicians think more comprehensively about complex spinal degeneration, but treatment decisions should still be individualized and grounded in the best available evidence.
The panel also identified important research gaps in cell-based therapies, including:
These limitations are why the guidelines use terms such as “fair” and “limited” evidence rather than presenting regenerative spine procedures as proven cures.
A potential candidate generally has:
The guidelines place strong emphasis on shared decision-making and patient education.
Regenerative treatment should not be chosen simply because a patient wants to avoid surgery or because a treatment is marketed as “natural” or “regenerative.”
Risks vary depending on the procedure.
ASIPP classifies:
Management of antiplatelet and anticoagulant medications should therefore be individualized based on:
One of the most important patient-safety messages in the guidelines involves regulatory compliance.
Regenerative medicine is often marketed as though:
are simply different versions of the same treatment.
They are not.
The guidelines discuss the FDA regulatory framework governing human cells and tissues and emphasize compliance with requirements involving:
Other regulatory considerations
[1]
The document also cautions against unapproved regenerative products.
The guideline does not recommend clinical use of non-approved products until adequate research and appropriate FDA authorization are established. [1]
For patients, that makes several questions essential:
Comprehensive
Regenerative medicine may occupy a space between conservative care and surgery, but it does not eliminate the need for surgical treatment.
A patient with a potentially treatable disc, facet joint, sacroiliac joint, or related degenerative pain generator may reasonably be evaluated for a regenerative approach after appropriate nonsurgical treatment.
However:
A biologic injection cannot mechanically decompress a severely compressed nerve or stabilize an unstable spine.
Surgical evaluation remains important when there is:
The goal should not be to “avoid surgery at all costs.”
The better goal is to identify the least invasive treatment that appropriately addresses the underlying problem while recognizing when regenerative treatment is unlikely to solve it.
Useful questions include:
These questions help shift the discussion away from whether “stem cells” or PRP simply work for back pain and toward whether a specific treatment is appropriate for a specific diagnosis.
Dr. Patel’s co-authorship of the 2025 ASIPP guidelines reflects his participation in a major multidisciplinary effort to establish a more rigorous framework for PRP, BMAC, and regenerative medicine for chronic low back pain.
The guidelines do not portray regenerative medicine as a universal solution.
Instead, they emphasize:
For patients considering regenerative treatment for chronic low back pain in Newport Beach or Orange County, the central question should not simply be:
“Do stem cells or PRP work for back pain?”
A better question is:
That is the more precise standard of care Dr. Patel helped advance through his work on the 2025 ASIPP consensus guideline.
PRP may be considered for certain causes of chronic low back pain, but the evidence depends on the anatomical target. Intradiscal PRP and epidural PRP received Level III, or fair, evidence with moderate recommendations in the 2025 ASIPP guidelines. [1]
Intradiscal BMAC received Level III/fair evidence and a moderate recommendation for selected patients with discogenic low back pain. [1]
Evidence for facet joint PRP is more limited. The guidelines assign Level IV, or limited, evidence to facet joint PRP. [1]
PRP for the sacroiliac joint also received Level IV/limited evidence. [1]
No. Regenerative treatment cannot mechanically decompress a severely compressed nerve or stabilize an unstable spine. Surgical evaluation remains important for progressive neurologic deficits, major neural compression, structural instability, and other conditions requiring mechanical correction.
No. PRP, autologous BMAC, exosomes, birth-tissue products, and manipulated or expanded cells are not interchangeable. The ASIPP guidelines emphasize regulatory compliance, product characterization, and caution with unapproved biologic products. [1]
PRP preparations can vary substantially in platelet concentration, total dose, white and red blood cell content, volume, and processing method. The guidelines emphasize documenting and standardizing these characteristics when possible.
Potential candidates generally have persistent, function-limiting symptoms associated with an identifiable pain generator and have not improved adequately with appropriate conservative care. Treatment should follow a thorough diagnostic evaluation. [1]
Dr. Shounuck Patel, DO is a leader in the field of orthopedic regenerative medicine.
Find out if you are a Regenerative Medicine candidate. We service Los Angeles County, Orange County, San Diego County and beyond. For more information contact our patient concierge at in**@***********er.com or call us at (310) 929-9790.